Henan Lingrui Pharmaceutical Co., Ltd.

SHSE:600285 Stock Report

Market Cap: CN¥12.0b

Henan Lingrui Pharmaceutical Balance Sheet Health

Financial Health criteria checks 6/6

Henan Lingrui Pharmaceutical has a total shareholder equity of CN¥2.9B and total debt of CN¥12.5M, which brings its debt-to-equity ratio to 0.4%. Its total assets and total liabilities are CN¥4.9B and CN¥2.0B respectively. Henan Lingrui Pharmaceutical's EBIT is CN¥709.0M making its interest coverage ratio -11.2. It has cash and short-term investments of CN¥956.8M.

Key information

0.4%

Debt to equity ratio

CN¥12.53m

Debt

Interest coverage ratio-11.2x
CashCN¥956.81m
EquityCN¥2.90b
Total liabilitiesCN¥1.98b
Total assetsCN¥4.89b

Recent financial health updates

No updates

Recent updates

An Intrinsic Calculation For Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Suggests It's 44% Undervalued

Oct 28
An Intrinsic Calculation For Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Suggests It's 44% Undervalued

Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Surges 33% Yet Its Low P/E Is No Reason For Excitement

Oct 13
Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Surges 33% Yet Its Low P/E Is No Reason For Excitement

If EPS Growth Is Important To You, Henan Lingrui Pharmaceutical (SHSE:600285) Presents An Opportunity

Aug 07
If EPS Growth Is Important To You, Henan Lingrui Pharmaceutical (SHSE:600285) Presents An Opportunity

A Look At The Fair Value Of Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285)

Jul 03
A Look At The Fair Value Of Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285)

Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Stock Catapults 27% Though Its Price And Business Still Lag The Market

May 07
Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Stock Catapults 27% Though Its Price And Business Still Lag The Market

Henan Lingrui Pharmaceutical's (SHSE:600285) Earnings May Just Be The Starting Point

May 02
Henan Lingrui Pharmaceutical's (SHSE:600285) Earnings May Just Be The Starting Point

Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 04
Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Held Back By Insufficient Growth Even After Shares Climb 27%

Should You Be Adding Henan Lingrui Pharmaceutical (SHSE:600285) To Your Watchlist Today?

Feb 29
Should You Be Adding Henan Lingrui Pharmaceutical (SHSE:600285) To Your Watchlist Today?

Financial Position Analysis

Short Term Liabilities: 600285's short term assets (CN¥2.3B) exceed its short term liabilities (CN¥1.9B).

Long Term Liabilities: 600285's short term assets (CN¥2.3B) exceed its long term liabilities (CN¥66.0M).


Debt to Equity History and Analysis

Debt Level: 600285 has more cash than its total debt.

Reducing Debt: 600285's debt to equity ratio has reduced from 9% to 0.4% over the past 5 years.

Debt Coverage: 600285's debt is well covered by operating cash flow (5226.3%).

Interest Coverage: 600285 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies